QT Prolongation in Critically Ill Patients With SARS-CoV-2 Infection.
Authors
Almuti, Khalid
ElRefaei, Hazem
Atallah, Bassam
Mohammad, Lana M
AlMahmeed, Wael
Badr, Mohamed
Abdallah, Khaled
Hamed, Fadi
Mallat, Jihad
Publication Date
2022Journal Title
J Cardiovasc Pharmacol Ther
ISSN
1074-2484
Publisher
SAGE Publications
Volume
27
Language
en
Type
Article
This Version
VoR
Metadata
Show full item recordCitation
El Nekidy, W. S., Almuti, K., ElRefaei, H., Atallah, B., Mohammad, L. M., AlMahmeed, W., Badr, M., et al. (2022). QT Prolongation in Critically Ill Patients With SARS-CoV-2 Infection.. J Cardiovasc Pharmacol Ther, 27 https://doi.org/10.1177/10742484211069479
Abstract
BACKGROUND: Several reports linked the use of repurposed drugs such as hydroxychloroquine (HCQ), azithromycin, lopinavir/ritonavir, and favipiravir with QT interval prolongation in patients with SARS-CoV2 infection. Little is known about the risk factors for QT interval prolongation in this population. We sought to describe the prevalence and identify the main risk factors associated with clinically significant corrected QT (QTc) prolongation in this population. METHODS: We conducted a retrospective analysis of critically ill patients who were admitted to our intensive care unit (ICU), had at least one electrocardiogram performed during their ICU stay, and tested positive for SARs-CoV-2. Clinically significant QTc interval prolongation was defined as QTc >500 milliseconds (ms). RESULTS: Out of the 111 critically ill patients with SARS-CoV-2 infection, QTc was significantly prolonged in 47 cases (42.3%). Patients with a clinically significant QTc prolongation had significantly higher proportions of history of cardiac diseases/surgery (22 [46.8%] vs. 10 [15.6%], P < .001), hypokalemia (10 [21.3] vs. 5 [7.8%], P = .04), and male gender (95% vs. 82.8%, P = .036) than patients with QTc ≤500 ms, respectively. A total of 46 patients (41.4%) received HCQ, 28 (25.2%) received lopinavir/ritonavir, and 5 (4.5%) received azithromycin. Multivariate logistic regression analysis showed that a history of cardiac disease was the only independent factor associated with clinically significant QTc prolongation (P = .004 for the likelihood-ratio test). CONCLUSION: The prevalence of clinically significant QTc prolongation in critically ill patients with SARS-CoV-2 infection was high and independent of drugs used. Larger prospective observational studies are warranted to elucidate independent risk factors associated with clinically significant QTc prolongation in this study population.
Keywords
Original Manuscript, QTc, prolongation, critically ill, COVID-19, SARS-CoV-2
Identifiers
10.1177_10742484211069479
External DOI: https://doi.org/10.1177/10742484211069479
This record's URL: https://www.repository.cam.ac.uk/handle/1810/333187
Rights
Licence:
https://creativecommons.org/licenses/by-nc/4.0/
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.
Recommended or similar items
The current recommendation prototype on the Apollo Repository will be turned off on 03 February 2023. Although the pilot has been fruitful for both parties, the service provider IKVA is focusing on horizon scanning products and so the recommender service can no longer be supported. We recognise the importance of recommender services in supporting research discovery and are evaluating offerings from other service providers. If you would like to offer feedback on this decision please contact us on: support@repository.cam.ac.uk